Ohr Pharmaceutical Inc. shares (NASDAQ:OHRP) snapped out of a months-long amble, jumping 62.6 percent to $3.69 Monday after a small midstage study showed that its lead candidate, OHR-102 (squalamine lactate ophthalmic solution 0.2 percent) eye drops, helped certain patients with macular edema receiving Lucentis (ranibizumab, Genentech Inc./Roche AG) achieve greater visual acuity gains than patients receiving Lucentis alone.